Dolutegravir is the newest integrase strand transfer inhibitor to be approved for the treatment
of human immunodeficiency virus (HIV) infection. Dolutegravir is equivalent or superior to …

Integrase strand transfer inhibitors (INSTIs) have improved the treatment of human
immunodeficiency virus (HIV). There are currently four approved for use in treatment-naïve …

Introduction Smoking tobacco and unhealthy alcohol use may negatively influence HIV care
continuum outcomes but have not been examined in combination. Methods Participants …

Background Once-daily, single-tablet regimens (STRs) have been associated with improved
patient outcomes compared to multi-tablet regimens (MTRs). This study evaluated real world …

Approximately one-quarter of people with HIV (PWH) in the US receive coverage through
the Medicare program; however, no prior real-world study has examined antiretroviral …

Background: Only 13% of HIV-positive young adults are estimated to be virally suppressed
and, even among those receiving medical care, HIV-positive young adults are less likely …

Atazanavir/cobicistat (ATV/c) and darunavir/cobicistat (DRV/c) are newly approved once
daily fixed-dose protease inhibitor combinations for the treatment of HIV-1 infection. Studies …

Objective: Whether the rate of HIV antiretroviral therapy (ART) persistence has improved
over time in the United States is unknown. We examined ART persistence trends between …

Single-tablet regimens (STRs) should be considered for patients with HIV/AIDS to increase
medication compliance and improve clinical outcomes. This study compared variations in …

Purpose To evaluate the real‐world rates of non‐adherence and non‐persistence to
antiretroviral therapy (ART) among treatment‐naïve adult patients with HIV after a 12‐month …